Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is a pioneering company dedicated to advancing non-opioid pain management and regenerative health solutions. Headquartered in Tampa, Florida, Pacira is committed to providing innovative treatments that minimize the reliance on opioids for pain relief, thereby redefining the role of opioids as a rescue therapy only.
Pacira has three primary commercialized products: EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and ioveraº®. EXPAREL, launched in 2012, is a long-acting local analgesic used for postsurgical pain management, offering significant reductions in opioid consumption and cumulative pain scores. ZILRETTA, approved in 2017, is an extended-release intra-articular injection aimed at managing osteoarthritis knee pain, providing extended pain relief without repeated administration. ioveraº is a novel handheld device that delivers precise, controlled doses of cold temperature to targeted nerves, offering immediate, drug-free pain relief.
The company’s advanced DepoFoam® delivery platform encapsulates drugs in a multivesicular liposome, releasing them over extended periods without altering their molecular structure. This technology underpins the efficacy of Pacira’s flagship product, EXPAREL, which has been pivotal in reducing opioid use and enhancing postoperative recovery.
Pacira continues to innovate with ongoing clinical developments and strategic initiatives. Recently, the company reported preliminary unaudited total revenue of $675.0 million for the fiscal year 2023. In 2024, Pacira plans to launch EXPAREL for two key lower extremity nerve blocks and anticipates the rollout of the NOPAIN Act in 2025, which will expand patient access to opioid-sparing pain management solutions.
Pacira’s commitment to developing non-opioid treatments is further demonstrated by its recent achievements in securing FDA and European Medicines Agency designations for PCRX-201, a gene therapy product candidate for osteoarthritis. The company’s focus on long-term growth and operational excellence remains steadfast under the leadership of CEO Frank D. Lee.
For more information on Pacira BioSciences and its product offerings, visit www.pacira.com.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 16, 2021, at 11:20 AM GMT. Live audio of the event can be accessed through the company’s website, with a replay available for two weeks after. Pacira is a leader in non-opioid pain management solutions, highlighted by its long-acting local analgesic, EXPAREL, launched in April 2012. The company aims to reduce opioid reliance through innovative therapies and technologies.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for October 2021, noting that EXPAREL achieved sales of $42.5 million, a 4.4% increase from $40.7 million in October 2020. Average daily sales for EXPAREL rose to 109% compared to last year. Sales of iovera° were $1.2 million, up from $1.0 million in the same period. CEO Dave Stack expressed confidence in strong growth ahead, citing improved market conditions for elective surgeries. The company also plans to integrate ZILRETTA post-acquisition of Flexion Therapeutics, aiming for annual growth in the high teens and over 50% operating margins.
Pacira BioSciences (Nasdaq: PCRX) has filed a lawsuit against eVenus Pharmaceutical Laboratories for patent infringement related to EXPAREL (bupivacaine liposome injectable suspension), protecting U.S. Patent Number 11,033,495, which expires on January 22, 2041. The lawsuit triggers a 30-month stay on eVenus’ ANDA approval under the Hatch Waxman Act. This marks a significant step in Pacira's patent strategy, as the company aims to defend its intellectual property against potential generic competition.
Pacira BioSciences (Nasdaq: PCRX) reported third quarter 2021 financial results, achieving total revenues of $127.7 million, compared to $117.5 million in Q3 2020. The company recorded a GAAP net income of $17.7 million ($0.40 per share) and adjusted EBITDA of $48.1 million, up from $34.2 million a year prior. The positive trajectory is bolstered by strong EXPAREL sales, reaching $121.9 million. A proposed acquisition of Flexion Therapeutics aims to enhance growth efforts. Pacira's financial outlook remains bullish while navigating ongoing challenges from the COVID-19 pandemic.
Pacira BioSciences (Nasdaq: PCRX) has received Notice of Allowance from the USPTO for a U.S. Patent Application related to the chemical composition of EXPAREL (bupivacaine liposome injectable suspension) and a novel manufacturing process. Upon issuance, these patents will be eligible for listing in the FDA Orange Book, extending patent protection until January 22, 2041. This move enhances the company's intellectual property strategy, securing barriers against competition. CEO Dave Stack emphasized confidence in EXPAREL's market leadership across various medical procedures.
Pacira BioSciences, Inc. (NASDAQ:PCRX) is set to release its third quarter financial results on November 3, 2021, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET to discuss the results. Participants can join the call by dialing the provided numbers or accessing the webcast via the Pacira investor website. Notably, Pacira emphasizes its leadership in non-opioid pain management, particularly with its long-acting analgesic EXPAREL® and the iovera°® cryoanalgesia system, highlighting its commitment to improving patient outcomes.
Pacira BioSciences (Nasdaq: PCRX) has announced its acquisition of Flexion Therapeutics for $8.50 per share in cash, plus a contingent value right (CVR) worth up to $8.00 per share, subject to certain milestones. This acquisition adds ZILRETTA, a non-opioid therapy for osteoarthritis knee pain, to Pacira's portfolio, enhancing its commitment to non-opioid pain management. The deal is expected to be accretive to earnings in 2022 and provides significant synergies. Pacira plans to fund the transaction from existing cash resources and expects it to close in Q4 2021, pending regulatory approvals.
TAMPA, Fla., Oct. 08, 2021 – Pacira BioSciences (NASDAQ: PCRX) announces an Investor Day on October 15, 2021, from 8:00 AM to 12:00 PM ET, at its Innovation and Training Center in Tampa. Key Opinion Leaders and the executive team will discuss updates on the company's commercial products and pipeline opportunities. Attendance is limited and requires advance registration. A live webcast and archived replay will be available on PaciraInvestorDay.com.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has received a Paragraph IV Certification Notice Letter from eVenus Pharmaceutical Laboratories regarding a generic version of EXPAREL (bupivacaine liposome injectable suspension). eVenus alleges the corresponding patent is invalid. Pacira is poised to defend its patent rights and has 45 days to initiate a lawsuit. The company possesses additional patents set to extend EXPAREL's market exclusivity into the 2040s, contributing to its competitive position in non-opioid pain management.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has successfully completed process validation for its EXPAREL product, marking a key milestone in increasing its manufacturing capacity. The new 200-liter production suite in Swindon, England, developed in partnership with Thermo Fisher Scientific, is operational, with sales expected to begin by year-end 2021. This expansion aims to achieve gross margins exceeding 85 percent by 2024. Additionally, a new Orange Book-listed patent extends EXPAREL's market exclusivity to January 2041.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
What is Pacira BioSciences, Inc. known for?
What are Pacira BioSciences' main products?
What is EXPAREL used for?
What recent financial milestone did Pacira achieve?
What is ZILRETTA?
How does ioveraº work?
What is the DepoFoam® delivery platform?
What are Pacira’s plans for 2024?
What is PCRX-201?
Where can I learn more about Pacira BioSciences?
